CISBIO Announces FDA Approval of MESOMARK®; Assay Now Available to Physicians in the U.S. for Monitoring Patients with Mesothelioma
Monday, March 26th, 2007.
Fujirebio Diagnostics, Inc.
Novel Treatments & Drugs
MESOMARK
Mesothelioma Blood Test
CISBIO, a developer and marketer of diagnostic assays for the quantification of tumor markers, announced that the MESOMARK® Assay, the world's first in vitro test for managing patients with mesothelioma, an aggressive and deadly form of cancer, has been approved by the United States Food and Drug Administration (FDA). The MESOMARK® test is developed and manufactured by Fujirebio Diagnostics, Inc. of Malvern, PA; CISBIO is the exclusive distributor of MESOMARK® in Europe, where it is currently undergoing evaluation for clinical use.
The MESOMARK® test is now accessible to physicians across the U.S. for monitoring patients who have been diagnosed with epithelioid or biphasic mesothelioma. This minimally-invasive tool requires only a blood sample.
The transition of the MESOMARK® test from research to clinical usage will be significant in managing mesothelioma, which mainly affects individuals who have been exposed to asbestos in the workplace. An estimated 10.000 new cases are diagnosed in industrialized countries each year. Although recent progress has been made in chemotherapy and surgical techniques for treatment, diagnosing and monitoring remain difficult. Current testing methods used to determine patient treatment can be invasive and costly.
The MESOMARK® Assay is a manual enzyme-linked immunosorbent assay (ELISA) that identifies a group of molecular markers called soluble mesothelin-related proteins (SMRP). Released into the bloodstream by mesothelioma cells, elevated levels of these proteins are found in cancer patients.
The approval was given under the FDA's Humanitarian Device Exemption (HDE) program, which authorizes companies to market medical devices to treat or diagnose diseases which meet certain criteria.
About CISBIO
CISBIO develops, manufactures and markets diagnostic assays for the quantification of tumor markers and other biomarkers in clinical biology. European leader in nuclear medicine, CISBIO is also an established developer of technologies that are used in assay development and drug screening procedures to enhance drug discovery. The company produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Headquartered in Saclay, France, CISBIO is owned by the Belgium consortium RadioPharma Partners. For more information contact CISBIO on +33 (0) 169857325.
MESOMARK® is a registered trademark of Fujirebio Diagnostics, Inc.
Most Recent in Drug Companies
Currently Recruiting: Mesothelioma Clinical Trials
Phase III Clinical Trial for Mesothelioma Available in 50 Locations Across the Globe
Phase 1 Clinical Trial For Those With Peritoneal Mesothelioma Underway
The Orphan Drug Act and the National Organization for Rare Disorders Bring Attention and Funding to Rare Diseases
Opdivo, Yervoy, and Keytruda: Immunotherapy Options for Mesothelioma
Most Recent in Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics Honored with Pioneer Award from Meso Foundation: MESOMARK® Test Recognized for Monitoring Patients with Asbestos-linked Cancer
NYU Study Validates Use Of Fujirebio Diagnostics' MESOMARK Test For Monitoring An Asbestos-Linked Cancer
NYU Study Validates Use of the Fujirebio Diagnostics MESOMARK® Test for Monitoring an Asbestos-Linked Cancer
Fujirebio Diagnostics Receives FDA Approval for the MESOMARK® Assay for the Management of Mesothelioma Patients
Most Recent in MESOMARK
Most Recent in Mesothelioma Blood Test
Metal-based Compound May Reduce Tumor Size in Pleural, Peritoneal Mesothelioma
Calretinin More Effective Than Mesothelin in Detecting Mesothelioma Early
New research suggests earlier mesothelioma diagnosis is a possibility
Gene Expression Ratio Test Predicts Post-Surgery Outcome in Mesothelioma
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Most Recent in Novel Treatments & Drugs
Universal Resource Indicator*